KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) EPS (Weighted Average and Diluted): 2009-2024

Historic EPS (Weighted Average and Diluted) for Neogenomics (NEO) over the last 14 years, with Dec 2024 value amounting to -$0.62.

  • Neogenomics' EPS (Weighted Average and Diluted) fell 50.00% to -$0.21 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.88, marking a year-over-year decrease of 44.26%. This contributed to the annual value of -$0.62 for FY2024, which is 11.43% up from last year.
  • As of FY2024, Neogenomics' EPS (Weighted Average and Diluted) stood at -$0.62, which was up 11.43% from -$0.70 recorded in FY2023.
  • In the past 5 years, Neogenomics' EPS (Weighted Average and Diluted) registered a high of $0.04 during FY2020, and its lowest value of -$1.16 during FY2022.
  • Over the past 3 years, Neogenomics' median EPS (Weighted Average and Diluted) value was -$0.70 (recorded in 2023), while the average stood at -$0.83.
  • As far as peak fluctuations go, Neogenomics' EPS (Weighted Average and Diluted) tumbled by 1,557.14% in 2022, and later spiked by 39.66% in 2023.
  • Over the past 5 years, Neogenomics' EPS (Weighted Average and Diluted) (Yearly) stood at $0.04 in 2020, then plummeted by 275.00% to -$0.07 in 2021, then tumbled by 1,557.14% to -$1.16 in 2022, then skyrocketed by 39.66% to -$0.70 in 2023, then grew by 11.43% to -$0.62 in 2024.